ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Economics"

  • Abstract Number: 0212 • ACR Convergence 2024

    Costs of Hospitalization in Patients with SLE: An Analysis of the National Inpatient Sample

    Brandon Blau1, Kelsey Gripp1, Catherine MacLean2 and Bella Mehta2, 1Hospital for Special Surgery, New York, NY, 2Hospital for Special Surgery, Weill Cornell Medicine, New York, NY

    Background/Purpose: Systemic lupus erythematosus (SLE) is associated with significant health care utilization, medical costs, and increased risk of hospitalization. We aimed to characterize the reasons…
  • Abstract Number: 1018 • ACR Convergence 2024

    Analysis of Medication Usage and Monthly Costs in Hospitalized Patients with Rheumatic Diseases: A Retrospective Observational Study

    Daniela Alejandra Salcedo-Soto1, Ana Cecilia Bardan-Inchaustegui2, Pablo Gamez-Siller3, Deynna Montserrat Lara Mendez4, Diana Elsa Flores-Alvarado5, Jorge Esquivel-Valerio6, Jesus Cardenas-de la Garza2 and Dionicio Galarza-Delgado7, 1Hospital Universitario Dr Jose Eleuterio Gonzalez, Monterrey, Mexico, 2Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, 3Facultad de Medicina UANL, Monterrey, Nuevo León, Mexico, 4Hospital Universitario Dr José Eleuterio González, Monterrey, Nuevo León, Mexico, 5Hospital Universitario Jose Eleuterio Gonzalez, Monterrey, Nuevo León, Mexico, 6Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, MONTERREY, Mexico, 7UANL Hospital Universitario, Monterrey, Nuevo León, Mexico

    Background/Purpose: Costs associated with rheumatic diseases significantly affect a considerable portion of patients’ income. The monthly income of northeastern Mexican families has been reported to…
  • Abstract Number: 1046 • ACR Convergence 2024

    Shifting Paradigms in Drug Spending: A Study of Medicare Part D versus Emerging Pharmacy Models in Rheumatology

    Katherine Schoeffler, Stephanie Beveridge, Max Bouvette, Veera Durga Vaishnavi Kurra, Reema Moussa, Ryan Johnson, Camille Goerend, Nimrah Bader and Ryan Nipp, University of Oklahoma College of Medicine, Oklahoma City, OK

    Background/Purpose: Recent policy changes and competitive alternative drug pricing models present the potential for medication cost savings. In this study, we sought to assess the…
  • Abstract Number: 1049 • ACR Convergence 2024

    Very Low Uptake of Biosimilar Adalimumab in the First 9 Months of Availability in Rheumatology

    Eric Roberts1, Gabriela Schmajuk2 and Jinoos Yazdany3, 1University of California, San Francisco, SF, CA, 2UCSF / SFVA, San Francisco, CA, 3UCSF, San Francisco, CA

    Background/Purpose: In 2021, over 300,000 patients in the United States used adalimumab, making it one of the highest-grossing drugs globally. In 2023, patent exclusivity for…
  • Abstract Number: 1870 • ACR Convergence 2024

    Costs and Healthcare Resource Utilization Associated with Inpatient and Day Hospitalizations of Patients with Lupus and Psychiatric Manifestations in France

    Nicoleta Petrica1, Nathan Cohen1, Maria Pini1, Minjee Park2, Mathieu Rosé3 and Jean-Francois Ricci2, 1Alira Health, Paris, France, 2Alira Health, Basel, Switzerland, 3Alira Health, Barcelone, Spain

    Background/Purpose: Lupus, a rare chronic autoimmune disorder, severely impacts patients' quality of life, productivity, and survival, placing a heavy burden on the healthcare system. Up…
  • Abstract Number: 1904 • ACR Convergence 2024

    Evaluation of the Economic Burden of Psoriatic Arthritis: Assessment of Direct Costs Using National Administrative Databases at National Level

    Wilson Bautista-Molano1, Ingrid Ramirez-bolivar2, Cristina Pinilla-Forero3 and Luz A Ruiz4, 1University Hospital Fundación Santa Fe de Bogotá, Bogotá, Colombia, 2Janssen, Bogotá, Colombia, 3Janssen, Bogotá, 4CODENTMED, Bogotá, Colombia

    Background/Purpose: Psoriatic arthritis (PsA) is a high-cost disease due to its significant impact on patients' quality of life and the extensive resources required for its…
  • Abstract Number: 2609 • ACR Convergence 2024

    Drivers of Infliximab Biosimilar Uptake: A Comparative Analysis of New Biosimilar Initiations versus Switching in a National Rheumatology Registry

    Eric Roberts1, Nick Bansback2, Chien-Wen Tseng3, Steve Shiboski4, Jing Li5, Gabriela Schmajuk6 and Jinoos Yazdany7, 1University of California, San Francisco, SF, CA, 2University of British Columbia, Vancouver, BC, Canada, 3University of Hawai'i John A. Burns School of Medicine, Honolulu, 4University of California, San Francisco, San Francisco, 5University of California, San Francisco, San Francisco, CA, 6UCSF / SFVA, San Francisco, CA, 7UCSF, San Francisco, CA

    Background/Purpose: Biosimilars hold promise for reducing pharmaceutical expenditures, however uptake has lagged. We analyzed the variability in new biosimilar starts and switching from bio-originator infliximab…
  • Abstract Number: 2682 • ACR Convergence 2024

    The Forgotten Costs of SLE: Estimating Indirect Costs in a National SLE Cohort

    Ann E. Clarke1, Yvan St-Pierre2, Megan Barber1, Sasha Bernatsky3, Evelyne Vinet4, Christian Pineau5, Murray Urowitz6, Dafna Gladman7, Christine Peschken8, John Hanly9, Alexandra Legge10 and Paul Fortin11, 1Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 2McGill University Health Center, Montreal, QC, Canada, 3Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 4McGill University Health Centre, Montreal, QC, Canada, 5McGill University, Montreal, QC, Canada, 6Self employed, Toronto, ON, Canada, 7University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 8University of Manitoba, Winnipeg, MB, Canada, 9Dalhousie University, Halifax, NS, Canada, Halifax, NS, Canada, 10Dalhousie University, Halifax, NS, Canada, 11Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada

    Background/Purpose: Economic analyses of SLE often include only direct healthcare costs.  Indirect costs, particularly those attributable to lost productivity in unpaid labour, are often overlooked,…
  • Abstract Number: 0173 • ACR Convergence 2023

    Review of Published Literature Reporting Economic Burden of Treatment Switching in Rheumatoid Arthritis

    Peter C. Taylor1 and Jenya Antonova2, 1Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 2Compass Strategy and Research, Inc., San Francisco, CA

    Background/Purpose: For rheumatoid arthritis (RA) American College of Rheumatology (ACR) recommends the treating to target approach, starting with conventional synthetic antirheumatic drugs (DMARDs). ACR advises…
  • Abstract Number: 0242 • ACR Convergence 2023

    Venous Thromboembolism in Patients with Gout in the US

    Alka Mithal1, Maanek Sehgal1, Brian LaMoreaux2 and Gurkirpal Singh1, 1ICORE, Woodside, CA, 2Horizon Therapeutics, Deerfield, IL

    Background/Purpose: Venous thromboembolism (VTE), manifested by deep venous thrombosis (DVT) and pulmonary embolism (PE), is a common medical problem with an estimated incidence of 1–2…
  • Abstract Number: 0335 • ACR Convergence 2023

    Meta-Analysis of the Cost-Effectiveness of Social Media Advertising as a Recruitment Tool

    Vladislav Tsaltskan1, Roel Baez2 and Gary Firestein1, 1University of California San Diego, San Diego, CA, 2UC San Diego Health, San Diego, CA

    Background/Purpose: Recruitment of study participants is challenging and can incur significant costs, particularly for studies of rheumatic disease or other rare conditions. Social media advertising…
  • Abstract Number: 0966 • ACR Convergence 2023

    The Burden of Oligoarticular Psoriatic Arthritis in the United States

    Abisola Olopoenia1, Ashley Martin2, Kate Orroth3, Cynthia Deignan4, Myriam Cordey5 and Dafna Gladman6, 1Cerner Enviza, North Kansas City, MO, 2BluePath Solutions, Los Angeles, CA, 3Amgen, Inc., Manhattan Beach, CA, 4Amgen, Inc., Agoura Hills, CA, 5Amgen, Inc., Thousand Oaks, CA, 6Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Patients with oligoarticular psoriatic arthritis (oligo PsA), defined as four or less joints involved, often do not meet criteria for entry in trials of…
  • Abstract Number: 2002 • ACR Convergence 2023

    Cost-Effectiveness Analysis of Sequential Treatment with Abaloparatide Followed by Alendronate in US Women and Men with Multiple Previous Fractures

    Mickael Hiligsmann1, Stuart Silverman2, Andrea J Singer3, Yamei Wang4, Leny Pearman4, John Caminis4 and Jean-Yves Reginster5, 1Maastricht University, Maastricht, Netherlands, 2Cedars-Sinai Medical Center and UCLA School of Medicine, Los Angeles, CA, 3MedStar Georgetown University Hospital, Washington, DC, 4Radius Health, Inc., Boston, MA, 5University of Liège, Liège, Belgium

    Background/Purpose: Patients with multiple previous fractures are at very high risk of subsequent fractures. Common treatment strategies for these patients include generic alendronate (ALN) monotherapy…
  • Abstract Number: 2169 • ACR Convergence 2023

    Cost-utility of a Progressive Spacing of Tocilizumab or Abatacept in Patients with Rheumatoid Arthritis in Sustained Remission: A Medico-economic Analysis of the Towards the Lowest Efficacious Dose Trial

    Joanna Kedra1, Benjamin Granger2, Lina El Houari3, Florence Tubach4 and Bruno Fautrel5, 1Sorbonne Université, IPLESP, and Pitié-Salpêtrière Hospital, Paris, France, 2Sorbonne Université, INSERM, and Pitié Salpêtrière Hospital, Paris, France, 3Institut Pierre Louis d’Epidémiologie et de Santé Publique, Paris, France, 4Centre de pharmaco-épidémiologie de l'APHP, Paris, France, 5Sorbonne Université APHP, Paris, France

    Background/Purpose: Biologic Disease Modifying Anti-Rheumatic Drugs (bDMARDs) progressive tapering is a real opportunity in people living with rheumatoid arthritis (RA) having achieved remission both from…
  • Abstract Number: 2266 • ACR Convergence 2023

    Direct Health Care Costs Differ by SLE Autoantibody Machine Learning Clusters in an International Inception

    May Choi1, Karen Costenbader2, Marvin Fritzler1, Yvan St. Pierre3, Murray Urowitz4, John G. Hanly5, Caroline Gordon6, Sang-Cheol Bae7, Juanita Romero-Diaz8, Jorge Sanchez-Guerrero9, Sasha Bernatsky3, Daniel Wallace10, David Isenberg11, Anisur Rahman12, Joan Merrill13, Paul R. Fortin14, Dafna Gladman15, Ian Bruce16, Michelle Petri17, Ellen Ginzler18, Mary Anne Dooley19, Rosalind Ramsey-Goldman20, Susan Manzi21, Andreas Jonsen22, Graciela S Alarcón23, Ronald van Vollenhoven24, Cynthia Aranow25, Meggan MacKay25, Guillermo Ruiz-Irastorza26, S. Sam Lim27, Murat Inanc28, Kenneth Kalunian29, Soren Jacobsen30, Christine Peschken31, Diane L. Kamen32, Anca Askanase33, Jill Buyon34 and Ann Clarke35, 1University of Calgary, Calgary, AB, Canada, 2Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 3Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 4Schroeder Arthritis Institute, Krembil Research Institute; University of Toronto Lupus Clinic; Division of Rheumatology, Toronto, ON, Canada, 5Dalhousie University, Halifax, NS, Canada, 6Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, 7Hanyang University Hospital for Rheumatic Diseases and Hanyang University Institute for Rheumatology Research, Department of Rheumatology, Seoul, South Korea, 8Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, 9University Health Network, Toronto, ON, Canada, 10Cedars-Sinai Medical Center, Los Angeles, CA, 11University College London, London, United Kingdom, 12Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, 13Oklahoma Medical Research Foundation, Oklahoma City, OK, 14Centre ARThrite - CHU de Québec - Université Laval, Quebec City, QC, Canada, 15Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, 16University of Manchester, Manchester, United Kingdom, 17Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, 18SUNY Downstate Health Sciences University, Brooklyn, NY, 19Raleigh Neurology Associates, Chapel Hill, NC, 20Northwestern University, Chicago, IL, 21Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, 22Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden, 23Heersink School of Medicine. The University of Alabama at Birmingham, Birmingham, AL, 24Amsterdam University Medical Centers, Amsterdam, Netherlands, 25Feinstein Institutes for Medical Research, Manhasset, NY, 26Hospital Universitario Cruces, Barakaldo, Spain, 27Emory University, Atlanta, GA, 28Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, 29University of California San Diego, La Jolla, CA, 30Rigshospitalet, Copenhagen, Denmark, 31University of Manitoba, Winnipeg, MB, Canada, 32Medical University of South Carolina, Charleston, SC, 33Columbia University Medical Center, New York, NY, 34NYU Grossman School of Medicine, New York, NY, 35University of Calgary, Division of Rheumatology, Cumming School of Medicine, Calgary, AB, Canada

    Background/Purpose: Using machine learning, we identified 4 patient clusters based on longitudinal autoantibody profiles in an international SLE inception cohort, which were predictive of disease…
  • 1
  • 2
  • 3
  • …
  • 9
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology